Imperial College London
Alternate

DrPaulKemp

Faculty of Medicine, National Heart & Lung Institute

Reader in the Molecular Biology of Muscles
 
 
 
//

Contact

 

+44 (0)20 7594 1716p.kemp

 
 
//

Location

 

115Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Witham:2022:10.3310/llbx6901,
author = {Witham, MD and Adamson, S and Avenell, A and Band, MM and Bashir, T and Donnan, PT and George, J and Hapca, A and Hume, C and Kemp, P and McKenzie, E and Pilvinyte, K and Rossios, C and Smith, K and Struthers, AD and Sumukadas, D},
doi = {10.3310/llbx6901},
journal = {Efficacy and Mechanism Evaluation},
pages = {1--82},
title = {Leucine and perindopril to improve physical performance in people over 70 years with sarcopenia: the LACE factorial RCT},
url = {http://dx.doi.org/10.3310/llbx6901},
volume = {9},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:sec id="abs1-1">                  <jats:title>Background</jats:title>                  <jats:p>Angiotensin-converting enzyme inhibitors and leucine are promising potential treatments for sarcopenia. Neither has yet been tested in adequately powered randomised trials in patients with sarcopenia.</jats:p>               </jats:sec>               <jats:sec id="abs1-2">                  <jats:title>Objectives</jats:title>                  <jats:p>To determine the efficacy of leucine and perindopril in improving physical function in older people with sarcopenia, to evaluate the effect of leucine and perindopril on muscle mass and to evaluate the predictive biomarkers of sarcopenia.</jats:p>               </jats:sec>               <jats:sec id="abs1-3">                  <jats:title>Design</jats:title>                  <jats:p>A placebo-controlled, parallel group, double-blind, randomised 2 × 2 factorial trial.</jats:p>               </jats:sec>               <jats:sec id="abs1-4">                  <jats:title>Setting</jats:title>                  <jats:p>Primary care and geriatric medicine secondary care departments in 14 UK centres.</jats:p>               </jats:sec>               <jats:sec id="abs1-5">                  <jats:title>Participants</jats:title>                  <jats:p>Adults aged ≥ 70 years with low muscle strength and mass, without contraindications to angiotensin-converting enzyme inhibitors and without known diagnosis-specific skeletal myopathy.</jats:p>               </jats:sec>               <jats:sec id="abs1-6">                  <jats:title>Interventions</jats:title>                  <jats:p>Eligible participants were randomised 1 : 1 to recei
AU  - Witham,MD
AU  - Adamson,S
AU  - Avenell,A
AU  - Band,MM
AU  - Bashir,T
AU  - Donnan,PT
AU  - George,J
AU  - Hapca,A
AU  - Hume,C
AU  - Kemp,P
AU  - McKenzie,E
AU  - Pilvinyte,K
AU  - Rossios,C
AU  - Smith,K
AU  - Struthers,AD
AU  - Sumukadas,D
DO  - 10.3310/llbx6901
EP  - 82
PY  - 2022///
SN  - 2050-4365
SP  - 1
TI  - Leucine and perindopril to improve physical performance in people over 70 years with sarcopenia: the LACE factorial RCT
T2  - Efficacy and Mechanism Evaluation
UR  - http://dx.doi.org/10.3310/llbx6901
VL  - 9
ER  -
Download